Tau Therapeutics LLC announced today that its academic collaborator, University of Virginia Professor Todd Bauer, MD, presented data at the 105th Annual Meeting of the American Association for Cancer Research (AACR), the premier cancer research event held in San Diego, California from April 5-9. His poster, entitled “Combination therapy with a MEK inhibitor plus T-type calcium channel inhibitor is highly effective in patient-derived pancreatic ductal adenocarcinomas,” concludes that combination therapy with the MEK inhibitor trametinib plus Tau’s T-type calcium channel inhibitor mibefradil results in significant growth inhibition of KRAS-mutant patient-derived pancreatic ductal adenocarcinoma orthotopic xenograft tumors in mice, including both treatment naïve tumors and tumors chronically exposed to prior trametinib and lapatinib.
Help employers find you! Check out all the jobs and post your resume.
